October 11, 2018
BASEL, Switzerland—Oct. 11, 2018—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that two abstracts containing Phase 2b data on patient-reported outcomes in psoriasis and atopic dermatitis from the company’s lead drug, tapinarof, will be presented in poster format during the upcoming 2018 Fall Clinical Dermatology Conference at the Wynn Hotel in Las Vegas from Oct. 18-21. Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under investigation for the treatment of psoriasis and atopic dermatitis.
Posters, dates/times, and location are listed below.
Patient-reported outcomes in subjects with plaque psoriasis treated with tapinarof cream: Results from a phase 2b, randomized parallel-group study. Neal Bhatia, M.D.,1 David Rubenstein, M.D., Ph.D.,2 Anna M. Tallman, Pharm.D.,3 James Lee, M.D., Ph.D.3
1Therapeutics Clinical Research, San Diego, CA; 2Dermavant Sciences, Inc., Durham, NC; 3Dermavant Sciences, Inc., New York, NY
Patient-reported outcomes in subjects with atopic dermatitis treated with tapinarof cream: Results from a phase 2b, randomized parallel-group study. Amy S. Paller, M.D.,1 Linda Stein Gold, M.D.,2 James Lee, M.D., Ph.D.,3 Anna M. Tallman, Pharm.D.,3 David Rubenstein, M.D., Ph.D.4
1Northwestern University Feinberg School of Medicine, Chicago, IL; 2Henry Ford Medical Center, West Bloomfield, MI; 3Dermavant Sciences, Inc., New York, NY; 4Dermavant Sciences, Inc., Durham, NC
Dermavant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for inflammatory skin diseases and medical dermatologic conditions. The company’s existing development pipeline consists of five product candidates targeting five different conditions with significant unmet medical needs. Dermavant’s lead product candidate, tapinarof (DMVT-505), is an investigational topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that is being developed as a first-line topical treatment for psoriasis and atopic dermatitis, which affect approximately 7.5 million and 28 million people in the United States, respectively.
For more information about Dermavant, please visit www.dermavant.com.